Open AccessAddition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
Author(s) -
Yang Wenjia,
Cai Xiaoling,
Gao Xueying,
Chen Yifei,
Chen Ling,
Ji Lig
Publication year - 2018
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12764
Subject(s) - medicine , insulin , hypoglycemia , glycated hemoglobin , postprandial , endocrinology , placebo , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , diabetes mellitus , glycemic , pharmacology , alternative medicine , pathology
Aims/Introduction To evaluate the efficacy and safety of combining insulin therapy with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors compared with combining insulin therapy with a placebo or other antihyperglycemic agents. Materials and Methods A literature search was carried out via electronic databases. The inclusion criteria were randomized controlled trials comparing the addition of DPP ‐4 inhibitors to insulin with the addition of a placebo or other active hypoglycemic agents to insulin therapy, study duration of no less than 12 weeks carried out in type 2 diabetes patients and the availability of outcome data to evaluate a change in the glycated hemoglobin. Results The glycated hemoglobin‐lowering efficacy was significantly greater with DPP ‐4 inhibitor/insulin ( DPP ‐4i/ INS ) than with placebo/insulin (weighted mean difference −0.53%, 95% confidence interval −0.63, −0.43, P < 0.01). The postprandial plasma glucose‐lowering efficacies was also significantly greater with DPP ‐4i/ INS than with placebo/insulin (weighted mean difference −1.65 mmol/L, 95% CI : −2.34, −0.96, P < 0.05). The risk of hypoglycemia or severe hypoglycemia was similar for DPP 4i/ INS and placebo/insulin treatments. There was no significant difference in the glycemia‐lowering efficacy between DPP ‐4i/ INS and alpha‐glucosidase inhibitors/insulin, thiazolidinedione/insulin and glucagon‐like peptide‐1 receptor agonist/insulin. Sodium–glucose cotransporter 2 inhibitor/insulin treatment achieved better placebo‐corrected efficacy in lowering postprandial plasma glucose, with less weight gain and no higher risk of hypoglycemia. Conclusions Treatment with DPP ‐4 inhibitors combined with insulin improved glycemic control without an increased risk of hypoglycemia or weight gain compared with insulin treatment alone.